Dear Editor, Patients who qualify for transapical transcather aortic valve replacement (TA-TAVR) are considered to be high-risk or inappropriate candidates for traditional aortic valve replacement surgery, frequently possessing poor peripheral arterial access excluding them from transfemoral TAVR (1) . Poor respiratory function has been shown to be a predictor of mortality in TA-TAVR patients (2) . The rate of chronic obstructive pulmonary disease in TA-TAVR patients ranges between 20-40% (1, 3, 4) . A recent single institution review found that epidural analgesia was associated with a decrease in respiratory complications, new onset atrial fibrillation and in hospital death (5) . However, epidural anesthesia in patients with severe aortic stenosis can result in problematic vasodilation and is not recommended in patients on clopidogrel therapy (6, 7) . Accordingly, single injection paravertebral analgesia with 0.2% ropivicaine with clonidine has been used safely since the initiation of the TA-TAVR program at the Maine Medical Center. Anaesthetic procedures adopted at Maine Medical Center for patients receiving transapical transcatheter aortic valve replacement have shown encouraging results suggesting clinical benefits of single injection paravertebral blockade (left sided paravertebral blocks between one and three levels at the discretion of the anesthesiologist), such as: decreased opiate administration, more frequent on table extubation, a lower rate of post-operative delirium, decreased rate of new onset atrial fibrillation, and a shorter ICU stay. In early observations there were no complications related to paravertebral blockades which are usually performed in a time efficient manner (15-30 minutes per patient). Addressing peri-operative sympathetic stimulation with neuraxial anesthesia may have a measurable salubrious benefit garnered beyond what is achieved with an opioidbased approach alone. The lack of complications at a minimum demonstrates the technique can be done safely in this high-risk patient cohort. Currently there is an on-going trial investigating the impact of paravertebral catheters in TA-TAVR patients on delirium and length of hospital stay (8) . This clinical trial highlights the growing interest in regional techniques for this very frail and highrisk patient cohort. However, clopidogrel therapy in the immediate post-operative period precludes the use of catheters at many centers. For this reason, a similar prospective trial is imperative to investigate the use of single injection paravertebral blockades, which may be applicable to more TAVR centers.
